Promatix Biosciences Unveils Promising Preclinical Results for PBS293 ADC

Promatix Biosciences Ltd has shared positive preclinical findings for its novel bispecific antibody-drug conjugate (ADC), PBS293-MMAE, at the 16th World ADC London Summit. This innovative treatment targets colorectal cancer, exploiting a dual-antigen approach to enhance selectivity and efficacy while minimizing toxicity.

The PBS293-MMAE was developed using a proteomics-based platform that identifies tumor surface proteins, aiming at stronger binding when EGFR and EphA2 are present on the same cancer cell. The approach shows promise in improving treatment outcomes for patients with metastatic colorectal cancer, offering a broader therapeutic reach than traditional therapies like cetuximab.

Data revealed PBS293-MMAE's superior potency and tumor growth inhibition over cetuximab-MMAE in both cell line and xenograft studies. Additionally, reduced toxicity in normal skin cells further supports its potential for tumor-specific action. These findings mark a significant advancement in devising targeted cancer therapies with enhanced safety and efficacy.